Display options
Cite
Brettler DB. Recombinant coagulation factor products. Haemophilia. 1995;1(3):155-8doi: 10.1111/j.1365-2516.1995.tb00059.x.
Brettler, D. B. (1995). Recombinant coagulation factor products. Haemophilia : the official journal of the World Federation of Hemophilia, 1(3), 155-8. https://doi.org/10.1111/j.1365-2516.1995.tb00059.x
Brettler, D B. "Recombinant coagulation factor products." Haemophilia : the official journal of the World Federation of Hemophilia vol. 1,3 (1995): 155-8. doi: https://doi.org/10.1111/j.1365-2516.1995.tb00059.x
Brettler DB. Recombinant coagulation factor products. Haemophilia. 1995 Jul;1(3):155-8. doi: 10.1111/j.1365-2516.1995.tb00059.x. PMID: 27214531.
Copy Download .nbib Format: NLM
Share it on

Haemophilia. 1995 Jul;1(3):155-8. doi: 10.1111/j.1365-2516.1995.tb00059.x.

Recombinant coagulation factor products.

Haemophilia : the official journal of the World Federation of Hemophilia

D B Brettler

Affiliations

  1. New England Hemophilia Center, The Medical Center of Central Massachusetts, 119 Belmont Street, Worcester, MA 01605-2892, USA.

PMID: 27214531 DOI: 10.1111/j.1365-2516.1995.tb00059.x

Abstract

There are numerous new coagulation factor concentrates that are being manufactured using recombinant technology. Some are available for use currently for the treatment of bleeding disorders and others are in clinical trials. Recombinant factor VIII concentrates are licenced in most countries and one FVIII concentrate with the B domain deleted should be available in the near future. Recombinant VIIa concentrate is in advanced phase III testing for the treatment of patients with inhibitor antibodies. Recombinant factor IX has been used successfully in animals and will be tested in humans shortly. This paper reviews these products and discusses their uses and possible side-effects.

Keywords: coagulation disorder; haemophilia; recombinant factor concentrate

Publication Types